Cargando…

Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance

Systemic therapy for metastatic triple-negative breast cancer (TNBC) still remains challenging because there are no targeted agents or endocrine therapies currently available. The present case report documents the successful use of cisplatin monotherapy to manage a heavily pretreated TNBC patient sh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baek, Dong Won, Park, Ji-Young, Lee, Soo Jung, Chae, Yee Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yeungnam University College of Medicine 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384912/ https://www.ncbi.nlm.nih.gov/pubmed/31962039 http://dx.doi.org/10.12701/yujm.2019.00423

Ejemplares similares

Impressive Response to Concomitant Platinum-based Chemotherapy and Yttrium-90 in a Patient with Heavily Pretreated Triple-negative Breast Cancer Widely Metastasized to the Liver
por: Castrellon, Aurelio, et al.
Publicado: (2017)

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient
por: Lolli, Ginevra, et al.
Publicado: (2020)

Phase II trial of utidelone as monotherapy or in combination with capecitabine in heavily pretreated metastatic breast cancer patients
por: Zhang, Pin, et al.
Publicado: (2016)

Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series
por: Yoo, Kwai Han, et al.
Publicado: (2015)

An Unexpected Tumor Reduction: Treatment with Olaparib Monotherapy in Heavily Pretreated BRCA2 Mutated Metastatic Pancreatic Cancer
por: Prete, Alessandra Anna, et al.
Publicado: (2022)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison
por: Usmani, Saad Z., et al.
Publicado: (2017)

Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer
por: Lee, Jin Sun, et al.
Publicado: (2021)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial
por: Liu, Yin, et al.
Publicado: (2023)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Phase II Study of Combination Chemotherapy with Etoposide and Ifosfamide in Patients with Heavily Pretreated Recurrent or Persistent Epithelial Ovarian Cancer
por: Kang, Heeseok, et al.
Publicado: (2009)

Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
por: Lee, Jung Ok, et al.
Publicado: (2019)

Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer
por: Shin, Wonkyo, et al.
Publicado: (2018)

Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer
por: Lee, Jieun, et al.
Publicado: (2017)

The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma
por: Oriol, Albert, et al.
Publicado: (2021)

Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma
por: Gil-Sierra, Manuel David, et al.
Publicado: (2022)

Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression
por: Park, Ji Hyun, et al.
Publicado: (2015)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Efficacy of Fulvestrant in Heavily Pretreated Postmenopausal Women with Advanced Breast Cancer: A Preliminary Report
por: Yoo, Changhoon, et al.
Publicado: (2011)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Cyclophosphamide, Methotrexate, and 5-Fluorouracil as Palliative Treatment for Heavily Pretreated Patients with Metastatic Breast Cancer: A Multicenter Retrospective Analysis
por: Park, Jin Hyun, et al.
Publicado: (2017)

MicroRNA-496 inhibits triple negative breast cancer cell proliferation by targeting Del-1
por: Lee, Soo Jung, et al.
Publicado: (2021)

Stereotactic Body Radiation Therapy for Patients with Heavily Pretreated Liver Metastases and Liver Tumors
por: Lanciano, Rachelle, et al.
Publicado: (2012)

Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights
por: Roviello, Giandomenico, et al.
Publicado: (2019)

MicroRNA-137 Inhibits Cancer Progression by Targeting Del-1 in Triple-Negative Breast Cancer Cells
por: Lee, Soo Jung, et al.
Publicado: (2019)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
por: Demir, Atakan, et al.
Publicado: (2020)

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
por: Smit, E. F., et al.
Publicado: (1998)

Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
por: Krawczyk, Katarzyna, et al.
Publicado: (2014)

Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients
por: Niu, Jiaxin, et al.
Publicado: (2015)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

Efficacy of salvage therapy with MTX-HOPE for elderly patients with heavily pretreated non-Hodgkin’s lymphoma
por: Fukunaga, Akiko, et al.
Publicado: (2020)

Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan
por: Takushima, Yusuke, et al.
Publicado: (2021)

CAR‐T treatment: Determining the progression‐free survival gain in patients with heavily pretreated multiple myeloma
por: Messori, Andrea
Publicado: (2020)

PB2262: PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT
por: Cerchione, C., et al.
Publicado: (2022)

Real-World Results of Raltitrexed Combined with S-1 and Bevacizumab in Heavily Pretreated Metastatic Colorectal Cancer
por: Liu, Xiu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mhcummothbtr7bsvjaeovrqv56